Demodulation of Jak, stat 3 and Akt signalling along with MAP kinase pathway cause paclitaxel resistance by STAT3 in breast cancer,13 and also the basal activity of JAK1/STAT1 and JAK1/STAT3 signalling is higher in chemo resistant cells. Here, JAK1 is linked to breast carcinoma.